Reporting our performance and impacts drives continuous improvement and communicates GSK's global EHS impacts to stakeholders. Internally, we use the data to inform senior management, to identify areas for improvement, to set and refine targets and to raise awareness.

EHS performance at GSK is measured using a series of EHS performance indicators selected based on

• Industry benchmarking and best practice.
• Assessment and prioritisation of our operations and our areas of greatest emissions.
• Guidelines set by external technical and professional organisations.

In 2002 we collected environmental data from 100 global manufacturing sites, including one that is closed, 24 research & development (R&D) facilities, 6 distribution centres, 1 drinks manufacturing facility and 3 main office buildings. We collected health and safety data from all of these locations as well as from 56 sales offices. An intranet data collection tool was used to collect and collate the global data.

In addition to the EHS data collected from sites, we collected GSK business travel air miles from Global Procurement, US fleet injury and illness information from Employee Health Management and product freight miles from Global Distribution. We also initiated a pilot programme in 2002 to collect core EHS data from five major contract manufacturers.

There were several sites that were closed or sold during 2002. Depending on the time of the sale or closure, the sites did not contribute materially to overall GSK aggregate emissions and resulting impacts and we collected data from only one.

The data were reviewed and analysed to determine the impacts on air, water and land. These impacts were compared to the impacts in previous years to assess our performance in the key areas of concern. In the process of providing 2002 data, GSK sites reviewed the data they reported in 2001. Corrections made as a result of this review improved the accuracy and consistency of the data and the impacts reported. For this reason, the 2001 baseline has been modified for certain performance measures. This is most evident in the new baseline for carbon dioxide. The other significant changes in the 2001 baseline data were ozone depletion potential, volatile organic compounds, wastewater chemical oxygen demand and non-hazardous waste. Minor changes were made to the 2001 baselines for energy, hazardous waste and waste recycled.

The 2002 data show that GSK is on track to meet the 2005 targets for most key performance indicators although we need to focus on phasing out the ancillary use of ozone depleting substances.